# NQO1

Source: https://onco.cc/targets/nqo1/  
OnCo record `nqo1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NQO1 (NAD(P)H dehydrogenase [quinone] 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Pancreatic ductal adenocarcinoma.

## Summary

Flavin-containing quinone reductase that catalyses two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species. Regulates cellular redox state primarily through quinone detoxification.

CIViC holds 3 clinical evidence items and 0 assertions across 3 variants, naming Amrubicin and NSC84167.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: NAD(P)H quinone dehydrogenase 1; NAD(P)H dehydrogenase [quinone] 1; QR1; NMOR1; DIA4
- Tags: cancer-genes-wave
- Symbol: NQO1
- Class: enzyme
- Biology: Flavin-containing quinone reductase that catalyses two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species. Regulates cellular redox state primarily through quinone detoxification. Reduces components of plasma membrane redox system such as coenzyme Q and vitamin quinones, producing antioxidant hydroquinone forms. In the process may function as superoxide scavenger to prevent hydroquinone oxidation and facilitate excretion. Alternatively, can activate quinones and their derivatives by generating redox reactive hydroquinones with DNA cross-linking antitumor potential. Location: Cytoplasm, cytosol (UniProt). Locus 16q22.1 (HGNC).
- Where found: Lung cancer: CIViC evidence names this disease; Pancreatic ductal adenocarcinoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:2874: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2874
- UniProt P15559: https://www.uniprot.org/uniprotkb/P15559/entry
- NCBI Gene 1728: https://www.ncbi.nlm.nih.gov/gene/1728
- Ensembl ENSG00000181019: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000181019

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- pathways: [KEAP1-NRF2 antioxidant pathway](https://onco.cc/pathways/keap1-nrf2/)

---
JSON: https://onco.cc/api/v1/entities/nqo1.json